Analytical Data
-
基因名
NAT8B
- Application
-
别名
NAT8B; CML2; Putative N-acetyltransferase 8B; Acetyltransferase 1; ATase1; Camello-like protein 2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UHF3
-
表达区间
1-227 aa
-
氨基酸序列
MAPYHIRKYQESDRKSVVGLLSGGMAEHAPATFRRLLKLPRTLILLLGGALALLLVSGSW ILALVFSLSLLPALWFLAKKPWTRYVDIALRTDMSDITKSYLSECGSCFWVAESEEKVVG TVGALPVDDPTLREKRLQLFHLSVDNEHRGQGIAKALVRTVLQFARDQGYSEVVLDTSNI QLSAMGLYQSLGFKKTGQSFFHVWARLVDLHTVHFIYHLPSAQAGRL
-
分子量
25.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NAT8B (N-acetyltransferase 8B) is a member of the N-acetyltransferase family, which plays a crucial role in the metabolism of drugs and endogenous compounds by catalyzing the transfer of an acetyl group from acetyl-coenzyme A to various substrates. The study of NAT8B has gained significance in recent years due to its potential implications in various diseases, including liver dysfunction and certain metabolic disorders. Variants in the NAT8B gene have been associated with altered enzyme activity, which may affect drug metabolism and predispose individuals to adverse drug reactions. Furthermore, NAT8B has been implicated in the pathophysiology of conditions such as non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma. Understanding the structure and function of NAT8B, as well as the mechanisms underlying its regulation, is essential for developing targeted therapies and personalized medicine approaches. Research on NAT8B recombinant proteins is pivotal to elucidating its enzymatic properties and interactions with potential inhibitors or substrate molecules. This knowledge may offer insights into therapeutic strategies to modulate NAT8B activity for better management of related diseases and improving pharmacotherapy outcomes. Overall, the exploration of NAT8B recombinant proteins serves as a cornerstone for advancing our understanding of its biological functions and clinical significance.
